Quick Answer
ENANTA PHARMACEUTICALS INC reported Total Revenue of $65.32 million for the year ending 2025.
- ENANTA PHARMACEUTICALS INC showed a decrease of -3.4% in Total Revenue from 2024 to 2025.
- This data is from ENANTA PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on November 19, 2025.
- XBRL data for this metric is available from 2011 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: $893.0 thousand | Q1 2014: $2.16 million | Q2 2014: $42.05 million | Q3 2014: $2.64 million | Q4 2014: $77.50 million | Q1 2015: $57.37 million | Q2 2015: $11.60 million | Q3 2015: $14.42 million | Q4 2015: $48.45 million | Q1 2016: $13.00 million | Q2 2016: $13.98 million | Q3 2016: $12.84 million | Q4 2016: $10.42 million | Q4 2016: $10.42 million | Q1 2017: $8.96 million | Q1 2017: $8.96 million | Q2 2017: $7.51 million | Q2 2017: $7.51 million | Q3 2017: $75.93 million | Q3 2017: $75.93 million | Q4 2017: $38.11 million | Q4 2017: $38.11 million | Q1 2018: $44.05 million | Q1 2018: $44.05 million | Q2 2018: $57.26 million | Q3 2018: $67.21 million | Q4 2018: $69.89 million | Q1 2019: $39.63 million | Q2 2019: $44.37 million | Q3 2019: $51.31 million | Q4 2019: $52.57 million | Q1 2020: $27.62 million | Q2 2020: $18.65 million | Q3 2020: $23.63 million | Q4 2020: $31.74 million | Q1 2021: $20.13 million | Q2 2021: $21.62 million | Q4 2021: $27.65 million | Q1 2022: $18.72 million | Q2 2022: $19.48 million | Q4 2022: $23.59 million | Q1 2023: $17.80 million | Q2 2023: $18.89 million | Q4 2023: $18.00 million | Q1 2024: $17.05 million | Q2 2024: $17.97 million | Q4 2024: $16.96 million | Q1 2025: $14.93 million | Q2 2025: $18.31 million | Q4 2025: $18.62 million.
- Over the full 17 years of available data (2011 to 2025), ENANTA PHARMACEUTICALS INC's Total Revenue has grown by 56.0%.
- Historical annual values: Fiscal year 2025: $65.32 million | Fiscal year 2024: $67.64 million | Fiscal year 2023: $79.20 million | Fiscal year 2022: $86.16 million | Fiscal year 2021: $97.07 million | Fiscal year 2020: $122.47 million | Fiscal year 2019: $205.20 million | Fiscal year 2018: $206.63 million | Fiscal year 2017: $102.81 million | Fiscal year 2017: $102.81 million | Fiscal year 2016: $88.27 million | Fiscal year 2016: $88.27 million | Fiscal year 2015: $160.88 million | Fiscal year 2014: $47.74 million | Fiscal year 2013: $32.05 million | Fiscal year 2012: $41.71 million | Fiscal year 2011: $41.88 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: